Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Carboplatin, Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies
NCT00072514Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2003
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, carboplatin, dexamethasone and rituximab in lymphoid malignancy, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Ability to Successfully Deliver the Investigational Therapy Without Incurring the Protocol Suspension Rules. Started Aug 2003; status: completed.
02
Drugs
gemcitabinecarboplatindexamethasonerituximab
03
Conditions
lymphoid malignancy
Beyond the preview
Go deeper on NCT00072514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072514.